EUVIMEDEUVIMED entdecken
Crossref

Predictive value of homologous recombination-related gene mutations in survival outcomes of first-line nivolumab plus chemotherapy for gastric cancer

Yuna Lee, Hyung-Don Kim, Sun Young Lee, Hyungeun Lee, Jaewon Hyung, Meesun Moon, Jinho Shin, Young Soo Park, Tae Won Kim, Min-Hee Ryu iD

Gastric Cancer · 2025

DOI: 10.1007/s10120-025-01648-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastric Cancer, 2025. Verfasst von Yuna Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Kor…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Nivolumab, Antineoplastic Combined Chemotherapy Protocols, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Asan Institute for Life Sciences, Asan Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Homologous recombination repair (HRR) gene mutations contribute to genomic instability. However, their clinical value in immune checkpoint inhibitor (ICI)-based treatments in gastric cancer remains unclear. Therefore, this study aims to investigate the efficacy of nivolumab plus chemotherapy according to the HRR mutation status in patients with advanced gastric cancer. METHODS: This single-center study included patients with gastric cancer with available panel sequencing results who were treated with first-line nivolumab plus chemotherapy (n = 115) or chemotherapy alone (n = 172). Mutation status of 17 HRR genes (BARD1, BLM, BRCA1, BRCA2, BRIP1, MRE11A, NBN, PALB2, PARP1, POLD1, RAD50, RAD51, RAD51C, RAD51D, RAD52, RAD54L, and XRCC2) was assessed using targeted next-generation sequencing. RESULTS: Among patients treated with nivolumab plus chemotherapy, 36.5% had HRR mutations, with BRCA2 mutation being the most common mutation (11.3%). Compared to those of the no-HRR mutation group, the HRR mutation group exhibited a higher objective response rate, longer progression-free survival (PFS) (median 12.8 vs. 6.5 months; hazard ratio HR 0.57), and overall survival (OS) (median not reached vs. 14.2 months; HR 0.40) with nivolumab plus chemotherapy. Patients with HRR mutations treated with nivolumab plus chemotherapy showed favorable PFS and OS compared to those treated with chemotherapy alone. However, this difference was not observed in patients without HRR mutations. CONCLUSIONS: HRR mutations were associated with favorable survival outcomes in patients treated with nivolumab plus chemotherapy. Our findings suggest that HRR mutations may serve as a potential predictive biomarker for first-line ICI-based chemotherapy in gastric cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsNivolumabAntineoplastic Combined Chemotherapy ProtocolsMutationRecombinational DNA RepairHumansFemaleMaleAgedMiddle AgedAdultPrognosisAged, 80 and overSurvival RateBiomarkers, TumorRetrospective Studies

Stichwörter der Autor:innen

Gastric cancerHRR mutationNivolumab plus chemotherapyPredictive biomarker

Substanzen

NivolumabBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
  • Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. miniryu@amc.seoul.kr.

ORCID-Profile: Min-Hee Ryu

Förderung

  • Asan Institute for Life Sciences, Asan Medical Center

Zitieren

APA

Lee, Y., Kim, H. D., Lee, S. Y., Lee, H., Hyung, J., Moon, M., Shin, J., Park, Y. S., Kim, T. W., & Ryu, M. H. (2025). Predictive value of homologous recombination-related gene mutations in survival outcomes of first-line nivolumab plus chemotherapy for gastric cancer. Gastric Cancer. https://doi.org/10.1007/s10120-025-01648-0

Vancouver

Lee Y, Kim HD, Lee SY, Lee H, Hyung J, Moon M, et al. Predictive value of homologous recombination-related gene mutations in survival outcomes of first-line nivolumab plus chemotherapy for gastric cancer. Gastric Cancer. 2025. doi:10.1007/s10120-025-01648-0

BibTeX
@article{Lee2025,
  author = {Lee, Yuna and Kim, Hyung-Don and Lee, Sun Young and Lee, Hyungeun and Hyung, Jaewon and Moon, Meesun and Shin, Jinho and Park, Young Soo and Kim, Tae Won and Ryu, Min-Hee},
  title = {Predictive value of homologous recombination-related gene mutations in survival outcomes of first-line nivolumab plus chemotherapy for gastric cancer},
  journal = {Gastric Cancer},
  year = {2025},
  doi = {10.1007/s10120-025-01648-0}
}
Kostenlos starten →